Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Risedronate Sodium: Expanding Horizons in Bone and Cancer Re
2026-08-05
Explore the advanced roles of Risedronate Sodium as a FPP synthase inhibitor in both bone metabolism and cancer research. This article delivers a deep, evidence-based analysis of its molecular action, translational applications, and protocol guidance for next-generation assays.
-
AO/PI Staining Solution: Redefining Cell Viability for Trans
2026-08-05
Explore how AO/PI Staining Solution, a dual fluorescent DNA dye reagent from APExBIO, is transforming the rigor and reproducibility of live/dead cell discrimination in translational research. This thought-leadership piece bridges mechanistic clarity, workflow strategy, and clinical relevance, with actionable guidance for optimizing fluorescence-based viability assays—especially in disease models such as diabetic nephropathy, where precise cell quantification underpins impactful discovery.
-
Canagliflozin as an SGLT2 Inhibitor: Advanced Diabetes Resea
2026-08-04
Canagliflozin is redefining diabetes and kidney research by combining potent SGLT2 inhibition with mitochondrial remodeling capabilities. Discover optimized workflows, troubleshooting tips, and actionable protocol parameters that leverage this dual-action compound for maximum assay sensitivity and translational relevance.
-
Diclofenac as a Non-Selective COX Inhibitor in Organoid Rese
2026-08-04
Diclofenac’s high purity and solubility make it an ideal tool for advanced cyclooxygenase inhibition assays in complex human iPSC-derived intestinal organoid models. This article details experimental setup, protocol parameters, troubleshooting, and the translation of new pharmacokinetic approaches for inflammation and pain signaling pathway studies.
-
Precision Control in Genome Editing with EZ Cap™ Cas9 mRNA (
2026-08-03
Explore how EZ Cap™ Cas9 mRNA (m1Ψ) enables unprecedented precision and temporal control in CRISPR-Cas9 genome editing. This article reveals new insights into mRNA nuclear export, specificity, and the practical implications for advanced gene editing workflows.
-
Optimizing Genome Editing with EZ Cap™ Cas9 mRNA (m1Ψ) R1014
2026-08-03
This article addresses common challenges in CRISPR-Cas9 genome editing, focusing on the scientific and workflow benefits of EZ Cap™ Cas9 mRNA (m1Ψ) (SKU R1014). Through scenario-driven Q&A, it demonstrates how mRNA with Cap1 structure and m1Ψ modification improves editing precision, immune evasion, and reproducibility, supporting reliable outcomes for biomedical researchers.
-
DMXAA (Vadimezan): Workflow Advances in Tumor Vasculature Di
2026-08-02
DMXAA (Vadimezan) sets a benchmark for targeted vascular disruption and apoptosis induction in cancer biology research. This guide delivers actionable workflows, troubleshooting insights, and integrates the latest endothelial STING-JAK1 findings to optimize your anti-angiogenic and immunomodulatory assays.
-
Ouabain: Unveiling Ion Transport Dynamics Beyond Standard As
2026-08-01
Explore the scientific depth of Ouabain as a selective Na+/K+-ATPase inhibitor, with a unique focus on dissecting cellular ion transport, signaling, and cardiac physiology. This article delivers method-level insight and comparative guidance for advanced research.
-
SN-38 Inhibits FUBP1-FUSE Binding: Mechanistic Insights in C
2026-07-31
This study uncovers that camptothecin and its analog SN-38, beyond inhibiting DNA topoisomerase I, also disrupt the interaction of the transcriptional regulator FUBP1 with its DNA target FUSE. These dual mechanisms may help explain the efficacy of SN-38 in models of advanced colon and liver cancer, offering new perspectives for targeted cancer research.
-
HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells
2026-07-31
This study elucidates how HDAC inhibition can reverse Epstein-Barr virus (EBV)-induced dedifferentiation in nasopharyngeal carcinoma (NPC) by targeting cancer cell plasticity at the epigenetic level. The findings provide both mechanistic insight and translational evidence for differentiation therapy in solid tumors, expanding the potential for epigenetic intervention beyond hematological malignancies.
-
Stereospecific 3-(2-methoxy-5-pyridyl)-alanine Modifications
2026-07-30
This study explores the incorporation of 3-(2-methoxy-5-pyridyl)-alanine at position 3 in degarelix-based GnRH antagonists, revealing significant stereochemistry-dependent effects on receptor antagonism and pharmacological duration. The findings provide actionable insights for peptide drug design and deepen our understanding of how unnatural amino acid substitutions modulate endocrine signaling.
-
NADPH Oxidase-ROS Activate L-Type Ca2+ Channels in Arterial
2026-07-30
This study elucidates how NADPH oxidase-derived reactive oxygen species (ROS) induce arterial contraction in early postnatal rats through activation of L-type voltage-gated calcium channels, independently of Rho-kinase, PKC, or Src-kinase pathways. These findings refine our understanding of vascular signaling in developing organisms and have implications for experimental design in kinase inhibitor and cell signaling pathway research.
-
HBsAg Hijacks TBK1 to Suppress Interferon and Induce Autopha
2026-07-29
This study uncovers how hepatitis B surface antigen (HBsAg) manipulates TANK-binding kinase 1 (TBK1) to suppress type I interferon production and trigger early autophagy, facilitating persistent HBV infection. The findings reveal a novel mechanism of immune evasion and highlight potential targets for antiviral intervention.
-
Aurora Kinase A Overexpression in Retinoblastoma: Therapeuti
2026-07-29
A recent study demonstrates that Aurora kinase A (AURKA) is consistently overexpressed in human retinoblastoma and closely correlates with histopathological high-risk factors and suboptimal chemotherapy response. These findings provide a strong rationale for targeting AURKA as a therapeutic strategy, particularly in advanced or refractory retinoblastoma.
-
Protoporphyrin IX: Precision Tool for Ferroptosis and Heme R
2026-07-28
Explore how Protoporphyrin IX empowers advanced studies in ferroptosis, heme formation, and photodynamic therapy. This in-depth guide reveals unique assay strategies and translational insights for researchers leveraging this pivotal photodynamic compound.